The latest call
FetchingOptimizeRx Corp reported on 2026年11月13日. We are fetching the call transcript; its summary follows once the transcript is in.
US$7.34-17.2%11月13日 收盘
数据截至2026年9月30日,来自2026年11月13日提交的10-Q
公司指引:2026 财年营收 US$87M 至 US$93M — 同比下降 17.8%(上年同期 US$109.4M)
Just reported
From OptimizeRx Corp's results release of 2026年11月13日; its quarterly report has since been filed.
Actual
US$21.6M
-17% y/y
+5.4% q/q
Guided
—
No guide given
Actual
US$0.06
+50% y/y
Guided
—
No guide given
Actual
US$2.7M
| 指标 | 截至该日的 3 个月2026年9月30日 | 截至该日的 3 个月2025年9月30日 | 变动 |
|---|---|---|---|
| 营业收入合计 | US$21.6M | US$26.1M | -17.08% |
| 利润 | US$1.2M | US$779K | +53.40% |
| 每股收益 | US$0.06 | US$0.04 | +50.00% |
| 自由现金流 | US$4.7M | US$3.2M | +47.99% |
这些是单季度数字,不是滚动一年——本站其他地方的数字覆盖十二个月,会大得多。季节性业务在两者之间摆动很大:ServiceNow 在十二月季度赚 20 亿美元自由现金流,在六月季度只有 5 亿。
对比对象是去年同一季度,而不是分析师预测。要说“超预期”或“不及预期”需要一致预期数据,那是我们没有的授权数据——而搞错它比不提更糟。
OptimizeRx Corp reported on 2026年11月13日. We are fetching the call transcript; its summary follows once the transcript is in.
OptimizeRx is a leading healthcare technology company that’s redefining how life science brands connect with patients and healthcare providers. Our platform combines innovative AI-driven tools like the Dynamic Audience Activation Platform (DAAP) and Micro-Neighborhood Targeting (MNT) to deliver timely, relevant, and hyper-local engagement. By bridging the gap between HCP and direct-to-consumer (DTC) strategies, we empower brands to create synchronized marketing solutions that drive faster treatment decisions and improved patient outcomes. Our commitment to privacy-safe, patient-centric technology ensures that every interaction is designed to make a meaningful impact, delivering life-changing therapies to the right patients at the right time. Headquartered in Waltham, Massachusetts, OptimizeRx partners with some of the world’s leading pharmaceutical and life sciences companies to transform the healthcare landscape and create a healthier future for all.
公司自己的描述,取自公告末尾。
引述和公司简介来自 OptimizeRx Corp 于 2026年11月13日 提交的第 2.02 项 8-K 文件;表格根据其季度报告编制。 在 EDGAR 上阅读公告 股价已按拆股和分红复权。
+29% y/y
Guided
—
No guide given
Full year 2026
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.